Search results for "APRI"

showing 10 items of 274 documents

30. un 110. panta nošķiršana Līgumā par Eiropas Savienības darbību

2016

Autors savā pētījumā „30. un 110. panta nošķiršana Līgumā par Eiropas Savienības darbību” veicis pētījumu par LESD 30. un LESD 110. panta piemērošanu un to savstarpēju nošķiršanu. Šī pētījuma mērķis bija analizēt LESD 30. un LESD 110. panta saturu un piemērošanu, kā arī noteikt konkrētus kritērijus, lai veiktu precīzu minēto pantu nošķiršanu. Pētījuma ietvaros autors izpētījis LESD 30. un LESD 110. panta vēsturisko attīstību. Apskatījis LESD 30. un LESD 110. panta piemērošanas raksturīgākos gadījumus, kā arī noteicis kritērijus pantu savstarpējai nošķiršanai. Autors galvenokārt izmantojis literatūru angļu valodā, analizējis Eiropas Savienības tiesas praksi, iepazinies ar tiesību zinātnieku …

Muitas nodokļiEiropas SavienībaMaksājums ar muitas nodokļiem līdzvērtīgu iedarbībuDiskriminējoši nodokļiJuridiskā zinātneBrīva preču aprite
researchProduct

Vēsture: Latvijas Universitātes Žurnāls, 2017, Nr.4

2017

Muižas Cēsu apriņķiskuģniecībaBaltijas Universitāte:HUMANITIES and RELIGION::History and philosophy subjects::History subjects [Research Subject Categories]Late Bronze Agelatviešu trimdaRecenzijassociālā palīdzībanational communityValstspapīru spiestuveNeatkarības karš - Latvijapadomju mitoloģija
researchProduct

Aprites ekonomika sabiedriskajā ēdināšanā kā pelnītspēju veicinošais faktors.

2022

Lai nodrošinātu sabiedriskās ēdināšanas uzņēmumu ilgtspējīgu izaugsmi, resursu izmantošanai jākļūst gudrākai un ilgtspējīgākai. Ir skaidrs, ka agrākais ekonomikas izaugsmes lineārais modelis vairs neder mūsdienu globalizētās pasaules sabiedrības vajadzībām. Nav iespējams izveidot nākotni, ņemot par pamatu modeli „paņemt, uztaisīt, izmest”. Daudzi dabas resursi ir ierobežoti, un ir jāatrod veids, kā tos izmantot no vides un ekonomikas viedokļa ilgtspējīgi. Izmantot esošos resursus labākajā iespējamajā veidā ir arī uzņēmumu ekonomiskajās interesēs. Maģistra darba mērķis ir izpētīt aprites ekonomikas lomu sabiedriskās ēdināšanas uzņēmumos, sabiedrības informētības līmeni, paradumus un viedokli…

NACE 5610pelnītspējaEkonomikaAprites ekonomikasabiedriskā ēdināšana
researchProduct

The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care

2020

Background & Aims NAFLD is a growing health concern. The aim of the Fatty Liver Assessment in Germany (FLAG) study was to assess disease burden and provide data on the standard of care from secondary care. Methods The FLAG study is an observational real-world study in patients with NAFLD enrolled at 13 centres across Germany. Severity of disease was assessed by non-invasive surrogate scores and data recorded at baseline and 12 months. Results In this study, 507 patients (mean age 53 years; 47% women) were enrolled. According to fibrosis-4 index, 64%, 26%, and 10% of the patients had no significant fibrosis, indeterminate stage, and advanced fibrosis, respectively. Patients with advanced fib…

NAFLD non-alcoholic fatty liver diseasemedicine.medical_specialtyBMI body mass indexNASH non-alcoholic steatohepatitisLiver fibrosisLSM liver stiffness measurementAST aspartate aminotransferaseLiver diseaseFLAG Fatty Liver Assessment in GermanyNAFLDALT alanine aminotransferaseInternal medicineAPRI aspartate-aminotransferase-to-platelet ratio indexInternal MedicineNAFL non-alcoholic fatty liverImmunology and AllergyMedicineddc:610Co-morbiditieslcsh:RC799-869FIB-4 fibrosis-4Disease burdenHepatologyFAST FibroScan-ASTGGT gamma-glutamyltransferasebusiness.industryFatty liverNASHGastroenterologyReal worldGLP-1 glucagon-like peptide-1T2DM type 2 diabetes mellitusCVE cardiovascular eventmedicine.diseaseMetabolic syndromeCohortlcsh:Diseases of the digestive system. GastroenterologyCAP controlled attenuation parameterSteatohepatitisMetabolic syndromebusinessBody mass indexResearch ArticleCohort studyJHEP Reports
researchProduct

Pharmacological and biochemical study on the effects of selective phosphodiesterase inhibitors on human term myometrium

1999

This study was aimed at evaluating the in vitro effects of phosphodiesterase inhibitors and beta2-adrenoceptor agonists on spontaneous contractions of human term myometrium. Rolipram, RP 73401 (3-cyclopentyloxy-N-(3,5(-dichloro-4-pyridil)-4-methoxybenzamide) and Ro 20-1724 (1-4-(3-butoxy-4-methoxybenzyl)-2-imidozolidinone) (phosphodiesterase 4 inhibitors) inhibited spontaneous myometrial contractions (Emax approximately 100%; pD2 of 6.80+/-0.28, 6.84+/-0.32 and 6.31+/-0.03, respectively). Salbutamol and formoterol were less effective (Emax=40+/-6% and 35+/-12%, respectively) than phosphodiesterase 4 inhibitors to reduce myometrial contractility. Inhibitors of phosphodiesterase 3 (milrinone …

Nitroprussidemedicine.medical_specialtyTocolytic agentPhosphodiesterase InhibitorsSiguazodanPhosphodiesterase 3In Vitro Techniqueschemistry.chemical_compoundPregnancyInternal medicinemedicineHumansDrug InteractionsRolipramPharmacologyChromatographyDose-Response Relationship DrugPhosphoric Diester HydrolasesPhosphodiesteraseGeneral MedicineAdrenergic beta-AgonistsIsoenzymesEndocrinologychemistryMyometriumMilrinoneFemaleSodium nitroprussideZaprinastmedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Interplay between Intestinal Bacterial Communities and Unicellular Parasites in a Morbidly Obese Population: A Neglected Trinomial

2022

Obesity is an epidemic causing a metabolic health crisis. Herein, the interactions between the gut prokaryotic and eukaryotic communities, metabolic comorbidities and diet were studied. Stool samples from 56 subjects, 47 with type III obesity and 9 with type II obesity and cardiovascular risk or metabolic disease, were assessed for the richness, diversity and ecology of the bacterial gut community through metagenomics, together with the study of the presence of common unicellular eukaryote parasites (Blastocystis sp., Dientamoeba fragilis and Giardia intestinalis) by qPCR. Clinical information regarding metabolic comorbidities and non-alcoholic hepatic fatty liver disease was gathered. To a…

Nutrition and DieteticsBacteriaMicrobiologiaObesity Morbidobesity; eukaryotic microbiota; <i>Blastocystis</i> sp.; <i>Giardia intestinalis</i>; <i>Dientamoeba fragilis</i>; metabolic markers; dietFecesDiabetes Mellitus Type 2BlastocystisAnimalsHumansObesitatParasitesFood ScienceDieta d'aprimament
researchProduct

Terminology and classification of miracle slimming diets: A narrative review and new proposals

2021

Introduction: In the last years, confusing or misleading use of the term called miracle or magic diets, using to weight loss treatment, has increased, along with several classification of them. Objectives: The purpose of this narrative review is to discuss miracle slimming diets and proposal new term and new classification for these diets. Methods: A narrative review up to September 2021 was carried out in the PubMed, Google Scholar, and Web of Knowledge. Furthermore, this strategy was complemented with a comprehensive search of the 'grey' literature [7] based in four different searching strategies: i) grey literature databases, ii) customized Google search engines, iii) targeted websites, …

ObesitatDieta d'aprimament
researchProduct

MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology.

2021

558 Background: Genomic platforms, such as Mammaprint (Agendia) (MP) and OncoType (Genomic Health) (OT), have been validated to determine the risk of relapse in therapeutic decision-making in early-stage hormone receptor positive (HR+), epidermal growth factor receptor 2 (HER2) negative breast cancer (BC). Discordances in risk allocation between these platforms affect up to 30% of patients. This study aims to develop the MamaPred test to improve the diagnostic performance of recurrence risk in HR+/HER2- early-stage BC. Methods: A total of 606 HR+/HER2- early-stage BC previously tested with OT [n = 287; Low Risk (LR) = 165, Intermediate Risk (IR) = 103 and High Risk (HR) = 19] and MP (n = 3…

OncologyCancer Researchmedicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.diseaseRecurrence riskBreast cancerOncologyMammaPrintInternal medicinemedicineRelapse riskStage (cooking)businessJournal of Clinical Oncology
researchProduct

Genomic profile of breast cancer: costeffectiveness analysis from the Spanish National Healthcare System perspective.

2014

Background: Costeffectiveness analysis of MammaPrint® (70-gene signature) in the diagnosis of early breast cancer as a prognosis assay to study the risk of tumor recurrence to administer adjuvant chemotherapy. Methods: Markov model assuming a cohort of 60-year-old women with breast cancer. Treatment costs and effects were assessed by comparing the 5-year, 10-year and lifetime risk of recurrence using Adjuvant! Online® (online algorithm), 70-gene signature or Oncotype DX® (21-gene assay). Results: 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene assay and online algorithm, with associated quality-adjusted life year gains up to 0.23 …

Oncologymedicine.medical_specialtyCost effectivenessCost effectivenessCàncer de mamaBreast cancerBreast cancerMammaPrintInternal medicinemedicinePharmacology (medical)Online algorithmEspanyaGynecologyPublic healthmedicine.diagnostic_testbusiness.industryHealth PolicyEconomic analysisGeneral MedicineCost-effectiveness analysisGenomicsAnàlisi cost-beneficimedicine.diseaseSalut públicaGenòmicaSpainCohortLife expectancyAnàlisi econòmicabusinessOncotype DX
researchProduct

In response: Genomic profile of breast cancer.

2015

Response to: Plun-Favreau J, Svedman C, Valentine W, Rouzier R. Genomic profile of breast cancer. Expert Rev Pharmacoecon Outcomes Res 2015;15(3):393–94We would like to express our gratitude for th...

Oncologymedicine.medical_specialtyNational Health Programsmedia_common.quotation_subjectBreast NeoplasmsBreast cancerMammaPrintInternal medicineGratitudemedicineBiomarkers TumorHumansPharmacology (medical)Genetic TestingPrecision Medicinemedia_commonmedicine.diagnostic_testbusiness.industryHealth PolicyGene Expression ProfilingGeneral MedicineHealth Care Costsmedicine.diseaseGenomic ProfileFemaleOncotype DXbusinessExpert review of pharmacoeconomicsoutcomes research
researchProduct